Novartis Slumps after Pulling Zelnorm

The pharma giant suspended U.S. sales of the irritable bowel syndrome treatment after the FDA said it may cause heart problems

Swiss pharmaceutical giant Novartis (NVS) said Mar. 30 it's suspended its U.S. marketing and sales of Zelnorm, a treatment for constipation caused by irritable bowel syndrome. The Food and Drug Administration suggested the treatment carries with it a risk of heart problems or strokes.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.